1. Market Research
  2. > Ulcers - Pipeline Review, H1 2013

Ulcers - Pipeline Review, H1 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 76 pages

Ulcers - Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Ulcers - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Ulcers, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ulcers. Ulcers - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope


- A snapshot of the global therapeutic scenario for Ulcers.
- A review of the Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Ulcers pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Ulcers.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Ulcers pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Ulcers - Pipeline Review, H1 2013
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Ulcers Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Ulcers 9
Ulcers Therapeutics under Development by Companies 11
Ulcers Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Ulcers Therapeutics - Products under Development by Companies 18
Ulcers Therapeutics - Products under Investigation by Universities/Institutes 19
Companies Involved in Ulcers Therapeutics Development 20
Sequella, Inc. 20
AstraZeneca PLC 21
Takeda Pharmaceutical Company Limited 22
Daewoong Pharmaceutical Co., Ltd. 23
Eisai Co., Ltd. 24
Ore Pharmaceuticals Inc 25
Ahn-Gook Pharmaceutical Co., Ltd. 26
Angelini Group 27
aRigen Pharmaceuticals, Inc. 28
Vecta Ltd. 29
Sihuan Pharmaceutical Holdings Group Ltd. 30
HeliCure AB 31
Ulcers - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Combination Products 33
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
vonoprazan - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
DWJ-206 - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
esomeprazole magnesium - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
esomeprazole magnesium - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
SQ-109 - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
ARH-1029 - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
Vecam - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
itriglumide - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
(acetylsalicylic acid + esomeprazole) - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
(acetylsalicylic acid + esomeprazole) - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
pantoprazole - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
Vaccine Against Helicobacter pylori - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
ebselen - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
PMKS-005 - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
Acid Pump Antagonists - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
Anaprazole - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
(lansoprazole + aspirin) - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
Compound-1 - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
Ulcers Therapeutics - Drug Profile Updates 61
Ulcers Therapeutics - Discontinued Products 66
Ulcers Therapeutics - Dormant Products 67
Ulcers - Product Development Milestones 69
Featured News and Press Releases 69
Jun 13, 2013: Xoma Initiates Pilot Trial Studying Gevokizumab In Patients With Pyoderma Gangrenosum 69
Jun 03, 2013: AstraZeneca Signs Agreement With Hanmi Pharma And Amneal Pharma In US NEXIUM Patent Litigation 69
May 29, 2013: Pozen Announces FDA Acceptance Of NDA Filing For PA8140 Tablets 70
May 29, 2013: Pozen Announces FDA Acceptance Of NDA Filing For PA32540 Tablets 70
Apr 29, 2013: Hanmi USA Receives FDA Tentative Approval For Esomeprazole Strontium Delayed Release Capsules 72
Mar 27, 2013: Takeda Submits New Drug Application For Fixed-dose Combination Of Takepron And Low-Dose Aspirin In Japan 72
Mar 25, 2013: Takeda Receives Decision From President Of National Tax Tribunal Related To Correction Notice On Transfer Pricing Of Prevacid 72
Mar 25, 2013: Takeda Receives Decision From President Of National Tax Tribunal Related To Correction Notice On Transfer Pricing Of Prevacid 73
Feb 05, 2013: Horizon Pharma Announces Receipt Of Additional US Patent Allowance For Duexis 73
Feb 05, 2013: Horizon Pharma Announces Receipt Of Additional US Patent Allowance For Duexis 74
Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75
Expert Panel Validation 75
Contact Us 76
Disclaimer 76

List of Tables


Number of Products Under Development for Ulcers, H1 2013 9
Products under Development for Ulcers - Comparative Analysis, H1 2013 10
Number of Products under Development by Companies, H1 2013 12
Number of Products under Investigation by Universities/Institutes, H1 2013 13
Comparative Analysis by Late Stage Development, H1 2013 14
Comparative Analysis by Mid Clinical Stage Development, H1 2013 15
Comparative Analysis by Early Clinical Stage Development, H1 2013 16
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 17
Products under Development by Companies, H1 2013 18
Products under Investigation by Universities/Institutes, H1 2013 19
Sequella, Inc., H1 2013 20
AstraZeneca PLC, H1 2013 21
Takeda Pharmaceutical Company Limited, H1 2013 22
Daewoong Pharmaceutical Co., Ltd., H1 2013 23
Ore Pharmaceuticals Inc, H1 2013 25
Ahn-Gook Pharmaceutical Co., Ltd., H1 2013 26
Angelini Group, H1 2013 27
aRigen Pharmaceuticals, Inc., H1 2013 28
Vecta Ltd., H1 2013 29
Sihuan Pharmaceutical Holdings Group Ltd., H1 2013 30
HeliCure AB, H1 2013 31
Assessment by Monotherapy Products, H1 2013 32
Assessment by Combination Products, H1 2013 33
Assessment by Stage and Route of Administration, H1 2013 35
Assessment by Stage and Molecule Type, H1 2013 37
Ulcers Therapeutics - Drug Profile Updates 61
Ulcers Therapeutics - Discontinued Products 66
Ulcers Therapeutics - Dormant Products 67
Ulcers Therapeutics - Dormant Products (Contd..1) 68

List of Figures


Number of Products under Development for Ulcers, H1 2013 9
Products under Development for Ulcers - Comparative Analysis, H1 2013 10
Products under Development by Companies, H1 2013 11
Products under Investigation by Universities/Institutes, H1 2013 13
Late Stage Products, H1 2013 14
Mid Clinical Stage Products, H1 2013 15
Early Clinical Stage Products, H1 2013 16
Discovery and Pre-Clinical Stage Products, H1 2013 17
Assessment by Monotherapy Products, H1 2013 32
Assessment by Combination Products, H1 2013 33
Assessment by Route of Administration, H1 2013 34
Assessment by Stage and Route of Administration, H1 2013 35
Assessment by Molecule Type, H1 2013 36
Assessment by Stage and Molecule Type, H1 2013 37

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.